Radiation Cystitis - Evaluation and Hematuria Management

Key Points

• Late radiation cystitis can present years after pelvic treatment and may cause severe hemorrhage.
• Never attribute gross hematuria to prior radiation without excluding recurrent/new malignancy, infection, stones, and upper-tract disease.
• Clot retention is an immediate drainage problem; restore bladder patency before prolonged diagnostic evaluation.
• Cystoscopy both characterizes radiation changes and identifies treatable bleeding sites or alternative pathology.
• Hyperbaric oxygen is an important tissue-healing option for persistent hemorrhagic radiation cystitis.
• Intravesical alum and other agents require specialist protocols and attention to renal function.
• Formalin, embolization, and urinary diversion are salvage strategies for refractory or life-threatening bleeding.
• Anticoagulants may worsen bleeding severity but do not remove the need to identify the source.

Algorithm

1. Assess hemodynamics, hemoglobin, renal function, infection signs, pain, and ability to void.
2. For clot retention, place an appropriate large-bore three-way catheter, manually evacuate clots, and begin continuous irrigation.
3. If drainage cannot be established or bleeding remains brisk, proceed to urgent cystoscopic clot evacuation and hemostasis.
4. Obtain urine testing and upper-tract imaging according to the clinical hematuria differential.
5. Perform cystoscopy to evaluate radiation telangiectasia and exclude tumor or other structural pathology.
6. Use cystoscopic therapy, intravesical agents, or hyperbaric oxygen for persistent clinically important bleeding.
7. Escalate to embolization or selected salvage procedures for refractory life-threatening hemorrhage.
8. Continue surveillance for recurrent bleeding, obstruction, bladder dysfunction, and malignancy.

Clinical Synopsis & Reasoning

Radiation cystitis reflects progressive endarteritis, mucosal ischemia, telangiectasia, fibrosis, and impaired healing in bladder tissue exposed to pelvic radiation. Mild irritative symptoms can occur acutely during treatment, but the clinically challenging syndrome is late hemorrhagic cystitis months or years later. Hematuria can be intermittent or brisk enough to cause clot retention, anemia, transfusion dependence, obstruction, or hospitalization.

A remote radiation history should raise suspicion but should never end the diagnostic workup. Patients previously treated for prostate, cervical, bladder, rectal, or other pelvic cancers remain at risk for recurrent disease and second urinary malignancies. Infection, nephrolithiasis, benign prostatic bleeding, anticoagulation, glomerular disease, and upper-tract tumors are competing diagnoses. Anticoagulants can worsen the amount of bleeding without being the underlying source.

Assess hemodynamics, urinary obstruction, pain, fever, renal function, hemoglobin, and ability to void. Gross hematuria with clots requires attention to catheter patency before extensive diagnostic testing. A large-bore three-way catheter, manual irrigation, and continuous bladder irrigation can clear clots and prevent obstruction. If the bladder cannot be cleared, cystoscopic clot evacuation and direct hemostasis are needed.

After stabilization, cystoscopy is central because radiation telangiectasias and friable mucosa can be recognized directly and suspicious lesions can be assessed. Upper-tract imaging is appropriate according to hematuria evaluation pathways. Urine culture should be obtained when infection is plausible. Severe suprapubic pain, fever, renal failure, or inability to drain the bladder suggests obstruction, perforation, infection, or another complication requiring urgent urologic care.

Treatment Strategy & Disposition

Mild chronic symptoms without major bleeding can be managed with avoidance of bladder irritants, treatment of infection if present, and symptom-directed therapy. Recurrent clinically important hematuria generally requires urology involvement. Cystoscopic fulguration or laser treatment can control focal telangiectatic bleeding. Intravesical agents such as alum may be used for diffuse hemorrhage in monitored settings; renal dysfunction increases concern for systemic aluminum toxicity.

Hyperbaric oxygen promotes neovascularization and tissue healing and is an established option for persistent radiation hemorrhagic cystitis when available, particularly before destructive salvage procedures are considered. Treatment requires multiple sessions and patient selection for pulmonary, ear, neurologic, and logistical considerations. Other intravesical or systemic therapies have variable evidence and should be used according to specialist protocol.

Life-threatening or refractory bleeding may require selective arterial embolization. Formalin can control severe hemorrhage but is caustic and carries substantial risk of bladder fibrosis, pain, reflux-related upper-tract injury, and fistula; it is reserved for highly selected refractory cases with appropriate evaluation. Cystectomy or urinary diversion is a last-resort option because surgery in irradiated tissue carries high complication risk.

Throughout care, correct anemia and coagulopathy, review anticoagulant/antiplatelet indications with the prescribing team, and avoid unnecessary traumatic catheterization. Long-term follow-up should address bladder capacity, urinary function, recurrent infections, renal obstruction, and recurrent bleeding.

Epidemiology / Risk Factors

• Radiation cystitis occurs after pelvic irradiation for prostate, gynecologic, bladder, rectal, and other malignancies.
• Late hemorrhagic disease is less common than transient acute urinary irritation but can be far more morbid.
• Risk increases with higher bladder dose, larger exposed volume, prior pelvic procedures, vascular disease, smoking, and some systemic therapies.
• Long cancer survivorship means clinicians may encounter radiation hematuria decades after treatment.

Investigations

Intravesical Options

Pharmacology

Prognosis / Complications

• Mild irritative symptoms often respond to conservative care.
• Many bleeding cases can be controlled with cystoscopic therapy or hyperbaric oxygen, but recurrence can occur.
• Severe refractory hemorrhage can cause chronic anemia, renal obstruction, repeated hospitalization, and major procedural morbidity.
• Early recognition of clot retention and progressive anemia reduces preventable complications.

Patient Education / Counseling

• Tell patients that any new visible blood in the urine deserves medical evaluation even if they were previously told they have radiation cystitis.
• Provide emergency instructions for inability to urinate, large clots, dizziness, syncope, fever, or rapidly increasing bleeding.
• Explain that hyperbaric therapy usually requires many sessions and works by improving tissue oxygenation and healing rather than cauterizing one vessel.
• Review anticoagulant and antiplatelet medicines, but advise patients not to stop them without a coordinated plan unless emergency clinicians direct otherwise.
• Encourage hydration as appropriate to cardiac and renal status during mild bleeding and avoid dehydration that can worsen clot formation.

Notes

The term “radiation cystitis” describes a mechanism, not a complete hematuria diagnosis. Patients with prior radiation can still develop bladder cancer, stones, infection, renal tumors, and benign urologic disease. Repeatedly treating “radiation bleeding” without a malignancy-appropriate evaluation is a preventable error.

Management should escalate according to bleeding physiology. A patient with pink urine and stable hemoglobin has a different problem from a patient with clot retention and transfusion dependence. The treatment ladder should reflect that difference and should involve urology early when bleeding is recurrent or functionally significant.

References

1. AUA and NCCN survivorship resources — Link
2. ASTRO survivorship toxicity resources — Link